Recognition of gain on sale of investment securities and decrease in valuation difference
First written in FY2019-Q3. 1 of 17 entries say "Worsened", first in FY2020-Q1. Latest entry: FY2027-H1.
2 other companies' latest entry also says "Other".
- FY2027-H1No gain on sale of investment securities in the interim periodAnnual report
「Gain on sale of investment securities 102 －」
Against the ¥102 million gain on the sale of investment securities in the same period of the previous year, no gain was recorded during the interim consolidated accounting period. - FY2026Higher Gains on Sales of Investment SecuritiesAnnual report
「Gain on sale of investment securities 1,402」
The gain on the sale of investment securities was ¥1,402 million, up from ¥1,112 million in the previous fiscal year. - FY2026-H1Decrease in gains on sales of investment securitiesAnnual report
「Gain on sale of investment securities 697 102」
The gain on the sale of investment securities decreased from ¥697 million in the same period of the previous year to ¥102 million. - FY2025Higher Gains on Sales of Investment SecuritiesAnnual report
「Gain on sale of investment securities 1,112」
The gain on the sale of investment securities was ¥1,112 million, up from ¥149 million in the previous fiscal year. - FY2025-H1Gain on Sale of Investment SecuritiesAnnual report
「Gain on sale of investment securities － 697」
During the interim consolidated accounting period, the company recorded a ¥697 million gain on the sale of investment securities. - FY2024-Q1Recognition of Impairment Loss on Investment SecuritiesAnnual report
「Loss on valuation of investment securities - 101」
During the cumulative first quarter of the current consolidated fiscal year, the company recorded a ¥101 million impairment loss on investment securities as an extraordinary loss. No such loss was recorded in the same period of the previous year. - FY2023Higher Gains on Sales of Investment SecuritiesAnnual report
「¥489 million gain on sale of investment securities」
The company recorded a ¥489 million gain on the sale of investment securities during the current consolidated fiscal year, up from ¥221 million in the previous fiscal year. - FY2023-Q3Gain on Sale of Investment SecuritiesAnnual report
「Gain on sale of investment securities － 121」
During the nine-month period, the company recorded a ¥121 million gain on the sale of investment securities. - FY2022Decrease in gains on sale of investment securities and valuation differencesAnnual report
「Other securities sold during the current consolidated fiscal year: sales amount ¥292 million; total gains on sale ¥221 million; total losses on sale ¥0 million」
The gain on the sale of investment securities decreased from ¥1,425 million in the previous consolidated fiscal year to ¥221 million, while the valuation difference on other securities also decreased from ¥3,801 million to ¥3,140 million. - FY2022-Q1Decrease in valuation difference on available-for-sale securitiesAnnual report
「Valuation difference on other securities △ 11 △ 497」
The valuation difference on other securities changed from a decrease of ¥11 million in the same period of the previous year to a decrease of ¥497 million in the first quarter of the current year. - FY2021Higher Gains on Sales of Investment SecuritiesAnnual report
「Other securities sold during the current consolidated fiscal year: sales amount ¥2,107 million; total gains on sale ¥1,425 million; total losses on sale ¥5 million」
The company recorded ¥2,107 million in sales of investment securities, ¥1,425 million in gains on sale and ¥5 million in losses on sale, and the gain on sale of investment securities increased from the previous fiscal year. - FY2021-Q2Recognition of gains and losses on the sale of investment securities; impairment loss no longer recognizedAnnual report
「Gain on sale of investment securities 23 Loss on sale of investment securities 19」
During the six months ended the second quarter, the company recorded a ¥23 million gain on the sale of investment securities and a ¥19 million loss on sale, while the ¥235 million impairment loss on investment securities recognized in the same period of the previous year was not recognized. - FY2021-Q1Decrease in the amount of impairment losses on investment securities recognizedAnnual report
「Impairment loss on investment securities 235 19」
The impairment loss on investment securities for the cumulative first quarter of the current consolidated fiscal year was ¥19 million, down from ¥235 million in the same period of the previous year. - FY2020-Q3Change in the amount of impairment losses on investment securities recognizedAnnual report
「Gain on sale of investment securities 412 197 Loss on sale of investment securities － 72 Impairment loss on investment securities 0 85」
For the nine months ended the third quarter, the company recorded a ¥197 million gain on the sale of investment securities, a ¥72 million loss on sale and an ¥85 million impairment loss. - FY2020-Q2Recognition of gains, losses and impairment losses on the sale of investment securitiesAnnual report
「Gain on sale of investment securities 197 Loss on sale of investment securities 72 Impairment loss on investment securities 172」
During the six months ended the second quarter of the current consolidated fiscal year, the company recorded a ¥197 million gain on the sale of investment securities, a ¥72 million loss on sale and a ¥172 million impairment loss. - FY2020-Q1WorsenedAnnual report
「Impairment loss on investment securities 235」
During the cumulative first quarter of the current consolidated fiscal year, the company recorded a ¥235 million impairment loss on investment securities as an extraordinary loss. - FY2019-Q3First statedAnnual report
「Gain on sale of investment securities 0 412 Valuation difference on other securities 1,392 △1,549」
During the nine months ended the third quarter of the current consolidated fiscal year, the company recorded a ¥412 million gain on the sale of investment securities, while the valuation difference on other securities decreased by ¥1,549 million.